| General Information | |
|---|---|
| ZINC ID | ZINC000071316362 |
| Molecular Weight (Da) | 461 |
| SMILES | COc1ccc(OC(F)(F)F)cc1Cn1c(C(=O)NCC(C)(C)O)cc2cc(C#N)ccc21 |
| Molecular Formula | C23F3N3O4 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 112.763 |
| HBA | 5 |
| HBD | 2 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 33 |
| LogP | 5.347 |
| Activity (Ki) in nM | 5.4954 |
| Polar Surface Area (PSA) | 96.51 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | - |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | - |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.696 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 15 |
| Fraction csp3 | 0.3 |
| Ilogp | 3.57 |
| Xlogp3 | 4.01 |
| Wlogp | 5.23 |
| Mlogp | 1.44 |
| Silicos-it log p | 4.01 |
| Consensus log p | 3.65 |
| Esol log s | -4.97 |
| Esol solubility (mg/ml) | 0.00495 |
| Esol solubility (mol/l) | 0.0000107 |
| Esol class | Moderately |
| Ali log s | -5.74 |
| Ali solubility (mg/ml) | 0.000841 |
| Ali solubility (mol/l) | 0.00000182 |
| Ali class | Moderately |
| Silicos-it logsw | -6.74 |
| Silicos-it solubility (mg/ml) | 0.0000844 |
| Silicos-it solubility (mol/l) | 0.00000018 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -6.27 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.13 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.307 |
| Logd | 3.684 |
| Logp | 4.239 |
| F (20%) | 0.012 |
| F (30%) | 0.005 |
| Mdck | - |
| Ppb | 99.16% |
| Vdss | 0.57 |
| Fu | 1.17% |
| Cyp1a2-inh | 0.448 |
| Cyp1a2-sub | 0.757 |
| Cyp2c19-inh | 0.874 |
| Cyp2c19-sub | 0.098 |
| Cl | 8.774 |
| T12 | 0.183 |
| H-ht | 0.972 |
| Dili | 0.539 |
| Roa | 0.089 |
| Fdamdd | 0.961 |
| Skinsen | 0.028 |
| Ec | 0.003 |
| Ei | 0.008 |
| Respiratory | 0.566 |
| Bcf | 0.917 |
| Igc50 | 3.515 |
| Lc50 | 4.851 |
| Lc50dm | 5.5 |
| Nr-ar | 0.027 |
| Nr-ar-lbd | 0.011 |
| Nr-ahr | 0.902 |
| Nr-aromatase | 0.89 |
| Nr-er | 0.178 |
| Nr-er-lbd | 0.007 |
| Nr-ppar-gamma | 0.108 |
| Sr-are | 0.26 |
| Sr-atad5 | 0.038 |
| Sr-hse | 0.02 |
| Sr-mmp | 0.493 |
| Sr-p53 | 0.894 |
| Vol | 440.684 |
| Dense | 1.046 |
| Flex | 0.5 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 3 |
| Qed | 0.555 |
| Synth | 2.686 |
| Fsp3 | 0.304 |
| Mce-18 | 24 |
| Natural product-likeness | -1.277 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |